Science Explorer Interactive view Map
Company · Suzhou · China

PersonGen (China)

persongen.comROR OpenAlex
Research works
17
▲ 1231% vs 2013–17
Citations
322
18.5 per fractional work
Top-10% rate
35.0%
record average 16.5%
Open access
53%
world 28%

Not ranked overall: PersonGen (China) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.32× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 18.47× its world share, 2 worksImmunology and Micro…Neuroscience: 1.29× its world share, 0 worksNeuroscienceComputer Science: 0.09× its world share, 0 worksComputer ScienceEngineering: 0.56× its world share, 1 worksEngineeringMathematics: 0.71× its world share, 0 worksMathematicsPhysics and Astronomy: 0.31× its world share, 0 worksPhysics and AstronomyMedicine: 2.93× its world share, 4 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 18.5×. Every wedge is a field page.

Which research topics does PersonGen (China) publish most on?

By volume in 2022–2025: CAR-T cell therapy research, Immunotherapy and Immune Responses, Glioma Diagnosis and Treatment and Monoclonal and Polyclonal Antibodies Research.

CAR-T cell therapy resea…2CAR-T cell therapy research: 2 fractional worksImmunotherapy and Immune…1Immunotherapy and Immune Responses: 1 fractional worksGlioma Diagnosis and Tre…0Glioma Diagnosis and Treatment: 0 fractional worksMonoclonal and Polyclonal Antibodies Research: 0 fractional worksVirus-based gene therapy research: 0 fractional worksAcute Lymphoblastic Leuk…0Acute Lymphoblastic Leukemia research: 0 fractional worksImmune Cell Function and Interaction: 0 fractional worksAcute Myeloid Leukemia Research: 0 fractional worksNeuroinflammation and Neurodegeneration Mechanisms: 0 fractional worksAdenosine and Purinergic Signaling: 0 fractional works
OncologyImmunologyGeneticsRadiology, Nuclear Medicine and Imaging4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 2 works
  2. 2 Immunotherapy and Immune Responses Immunology 1 works
  3. 3 Glioma Diagnosis and Treatment Genetics 0 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  5. 5 Virus-based gene therapy research Genetics 0 works
  6. 6 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 0 works
  7. 7 Immune Cell Function and Interaction Immunology 0 works
  8. 8 Acute Myeloid Leukemia Research Hematology 0 works
  9. 9 Neuroinflammation and Neurodegeneration Mechanisms Neurology 0 works
  10. 10 Adenosine and Purinergic Signaling Physiology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available52.6%not open47.4%

World: 28% of research is openly available.

with international co-authors26.1%domestic only73.9%

World: 19% is written across borders.

How has PersonGen (China)'s research output changed?

Output in 2018–2022 was 1231% higher than in 2013–2017.

2005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Suzhou

All research institutions in Suzhou

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.